Featured Research

from universities, journals, and other organizations

New class of antiangiogenesis drugs: Natural plant compound blocks blood vessel growth by interfering with cellular adhesion

Date:
July 1, 2011
Source:
Massachusetts General Hospital
Summary:
Researchers have discovered the first of an entirely new class of anti-angiogenesis drugs -- agents that interfere with the development of blood vessels. The investigators describe how a compound derived from a South American tree was able, through a novel mechanism, to interfere with blood vessel formation in animal models of normal development, wound healing and tumor growth.

Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs -- agents that interfere with the development of blood vessels. In a report in Proceedings of the National Academy of Sciences/Early Edition, the investigators describe how a compound derived from a South American tree was able, through a novel mechanism, to interfere with blood vessel formation in animal models of normal development, wound healing and tumor growth.

"Most of the FDA-approved antiangiogenesis drugs inhibit the pathway controlled by vascular endothelial growth factor or VEGF, which directly stimulates blood vessel development," says Igor Garkavtsev, MD, PhD, of the Steele Laboratory for Tumor Biology at MGH, lead author of the study. "Although these drugs have become standard treatments for several types of cancer, they only provide modest benefit in terms of extending patient survival, so more effective drugs targeting tumor vasculature are needed."

While tumors need to generate and maintain their own blood supply to keep growing, tumor vasculature tends to be highly disorganized, which interferes with the effectiveness of traditional treatments like radiation and chemotherapy. Drugs that target the VEGF pathway can "normalize" tumor vasculature and improve the effectiveness of other therapies, but in addition to their limited effect on patient survival, such agents also can generate resistance or have toxic effects.

In their search for drugs that block blood vessel growth in different ways, Garkavtsev and his colleagues focused on pathways involved with the adhesion of endothelial cells that line blood vessels to the outer vessel wall. Appropriate cellular adhesion is essential to blood vessel function, and cells lining the tangled vessels characteristic of tumors often exhibit altered adhesion. Using a novel two-step strategy, the team first screened 50,000 compounds to find those affecting cellular adhesion and then analyzed identified compounds for toxicity and for their effects on actin, a protein essential to cellular structure.

One of two compounds identified by this process was dehydro-alpha-lapachone (DAL), derived from Tabebuia avellanedae, a tree native to Argentina and Brazil. Since DAL has structural similarities to another agent with antitumor activities and did not appear to be toxic, it was chosen for further investigation. The researchers first showed that DAL administration interfered with blood vessel formation in zebrafish, both during embryonic development and wound healing. They then found that it reduced the vascular density of tumors implanted in mice and, with daily treatment, significantly reduced tumor growth with no signs of toxicity.

Experiments with endothelial cells from human umbilical veins revealed that DAL administration altered the size and shape of the cells by changing the organization of the actin cytoskeleton; blocked formation of new vascular networks and reorganized existing networks; and interfered with the movement of cells required for wound healing. Further investigation found that DAL produces these effects by decreasing the activity of Rac1, a protein known to be important to cellular adhesion and cytoskeletal organization.

"This work is the first to discover the antivascular effects of DAL and its target Rac1, and our data strongly suggest that DAL promotes Rac1 degradation," says Rakesh Jain, PhD, director of the Steele Lab and senior author of the study. "DAL has the potential to improve treatment of many types of cancer and of other diseases characterized by abnormal blood vessels." Jain is the Cook Professor of Radiation Oncology (Tumor Biology) and Garkavtsev is an assistant professor of Radiation Oncology at Harvard Medical School

Additional authors of the PNAS study are Vikash Chauhana and Hon Kit Wong, PhD of the Steele Lab; Arpita Mukhopadhyay, PhD, and Randall Peterson, PhD, MGH Cardiovascular Research Center, and Marcie A. Glicksman, PhD, Partners Center for Drug Discovery and Brigham and Women's Hospital. The research was supported by grants from the Department of Defense, the National Institutes of Health, and Partners HealthCare.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. I. Garkavtsev, V. P. Chauhan, H. K. Wong, A. Mukhopadhyay, M. A. Glicksman, R. T. Peterson, R. K. Jain. Dehydro--lapachone, a plant product with antivascular activity. Proceedings of the National Academy of Sciences, 2011; DOI: 10.1073/pnas.1104225108

Cite This Page:

Massachusetts General Hospital. "New class of antiangiogenesis drugs: Natural plant compound blocks blood vessel growth by interfering with cellular adhesion." ScienceDaily. ScienceDaily, 1 July 2011. <www.sciencedaily.com/releases/2011/07/110701121818.htm>.
Massachusetts General Hospital. (2011, July 1). New class of antiangiogenesis drugs: Natural plant compound blocks blood vessel growth by interfering with cellular adhesion. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2011/07/110701121818.htm
Massachusetts General Hospital. "New class of antiangiogenesis drugs: Natural plant compound blocks blood vessel growth by interfering with cellular adhesion." ScienceDaily. www.sciencedaily.com/releases/2011/07/110701121818.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins